How Big Tobacco
lobbies governments

The most visible face of industry influence is direct lobbying — registered meetings between tobacco company representatives and elected officials, commissioners and ministerial staff. All five major tobacco corporations maintain lobbying operations in Brussels and in national capitals. In the European Union, the tobacco industry collectively declares approximately €14 million in annual lobbying expenditure and operates through at least 49 documented organisations, including trade associations, consultancies and third-party groups.

Between 2023 and 2024, tobacco lobbyists held at least 257 meetings with EU decision-makers — many of which were not publicly disclosed. A 2025 report by STOP and Contre-Feu identified that of 70 meetings recorded between Member States and tobacco lobbyists in 2024–2025, 18 were with Italian MEPs and 8 with German MEPs. PMI, BAT and JTI all maintain active EU affairs teams; Philip Morris International, British American Tobacco and Japan Tobacco International are among the highest-spending tobacco lobbyists in the EU Transparency Register.

Direct lobbying is complemented by indirect channels: trade associations submitting consultation responses, think tanks providing testimony, and third-party organisations framing issues in ways that advance industry interests.

The tobacco industry pioneered the playbook of manufacturing scientific doubt — a strategy with a documented history stretching back to the 1950s, when the major cigarette companies collectively funded research designed to cast doubt on the emerging consensus linking smoking to lung cancer. Internal documents released through US litigation confirmed that executives knew their products caused cancer while publicly disputing the evidence.

All five major tobacco corporations fund scientific research — particularly on their smoke-free product lines. PMI has declared over $14 billion in research investment since 2008, focused primarily on demonstrating that IQOS is less harmful than cigarettes. BAT funds its own research programmes on Vuse and glo; JTI runs product development research on Ploom. The concern is not research per se, but the funding of research specifically designed to support regulatory outcomes favourable to industry products, channelled through foundations and institutions that obscure the relationship.

The clearest documented case involves the Foundation for a Smoke-Free World — established and entirely funded by PMI, which provided it approximately $182 million. Despite claiming independence, TCRG and STOP analyses documented sustained alignment between the Foundation's grant-making and PMI's regulatory priorities. Several major grantees, including the Centre of Excellence for the Acceleration of Harm Reduction (CoEHAR) at the University of Catania (which received over $30 million), had well-documented ties to the tobacco industry prior to receiving funding.

The broader issue is structural: researchers who receive industry funding — directly or through intermediaries — are more likely to produce results favourable to industry products. Conflict-of-interest disclosure in publications on tobacco and nicotine remains inconsistent.

The WHO Framework Convention on Tobacco Control, ratified by 182 countries, is the primary international instrument for tobacco regulation. Article 5.3 of the Convention obliges governments to protect public health policies from tobacco industry interference — requiring that interactions with the industry be limited and disclosed. Tobacco companies treat COP sessions as opportunities to influence the trajectory of global tobacco regulation, and their documented presence — direct and indirect — at these negotiations is well established.

At COP10 in Panama (2023), documented interference included organised campaigns against the Convention process by organisations with undisclosed or tobacco-linked funding. The COPWATCH website, which published sustained criticism of COP proceedings without disclosing its funders, is one documented example. The Centre of Excellence for the Acceleration of Harm Reduction (CoEHAR) — a recipient of over $30 million from the PMI-funded Foundation for a Smoke-Free World — also sent advocacy communications to EU officials during the COP period.

At the national level, industry lobbying targets FCTC implementation — pressuring governments to interpret provisions narrowly, delay domestic legislation, or refrain from regulatory measures they consider commercially threatening.

One of the tobacco industry's most powerful and underreported tactics is the weaponisation of international trade law to challenge domestic health legislation. Under investor-state dispute settlement (ISDS) mechanisms embedded in bilateral investment treaties, tobacco companies have sued governments for enacting public health measures — framing regulations as expropriation of their intellectual property or commercial rights.

Philip Morris International filed investor-state claims against both Australia and Uruguay after they introduced plain packaging and graphic health warning requirements. The aim was not necessarily to win — it was to impose enormous legal costs and signal to other governments that similar measures would trigger litigation. The chilling effect on smaller, lower-income countries has been well documented.

The strategy extends to trade agreements. Industry representatives have lobbied to include provisions in bilateral and multilateral trade deals that limit governments' ability to restrict tobacco marketing, advertising or packaging — effectively embedding industry-friendly rules in treaties that are harder to amend than domestic legislation.

Wherever the industry faces tighter regulation, a consistent argument follows: the economic consequences for workers, farmers, retailers and tax revenues. Tobacco companies present themselves as significant employers and major contributors to government coffers through excise taxes — an argument deployed in national consultations, at trade hearings, and in direct communications with finance and agriculture ministries.

Investment announcements are a common illustration of the tactic. PMI announced a €1 billion factory investment in Bologna, Italy — publicly during a period of active EU regulatory discussions, in a country that accounted for a significant share of documented tobacco lobbying meetings. BAT, JTI and Imperial Brands similarly emphasise their employment and tax contributions in national consultations, particularly when facing excise increases or marketing restrictions.

The economic argument systematically omits the other side of the ledger: the healthcare costs of tobacco-related disease, lost productivity, environmental damage from tobacco production and cigarette waste, and the social costs borne by public health systems. Independent analyses consistently show that the net economic impact of tobacco on most economies is negative. The claim that the industry "contributes" through tax revenue ignores that the taxes exist specifically to offset a fraction of the damage it causes.

The tobacco industry systematically recruits former government officials, regulators, health ministry staff and parliamentary advisers — and conversely places its own former executives in positions of influence across regulatory bodies, international organisations and academic institutions. This movement between sectors creates networks of access, trust and shared interest that persist long after formal employment ends.

The reverse flow matters equally: former industry employees take roles in institutions meant to regulate or scrutinise them. At the EU level, multiple documented cases exist of individuals moving between tobacco company roles, industry-funded foundations and positions in health or trade policy bodies. The WHO itself has documented repeated attempts by former industry employees to gain access to FCTC processes in advisory or observer capacities.

Consulting firms with established tobacco industry relationships occupy a parallel space. McKinsey & Company has worked for PMI, BAT, RJ Reynolds, JTI and several other major tobacco companies over several decades, helping to design marketing strategies, enter new markets and manage regulatory environments — while simultaneously advising governments, health organisations and international bodies on public health.

The tobacco industry consistently invokes the threat of illicit trade — smuggling, counterfeiting and tax evasion — to oppose tobacco control measures. The argument runs that high taxes and strict regulation drive consumers to illegal markets, undermining both public health goals and government revenue. Industry-funded research and advocacy groups amplify this claim, often without disclosing the source of their funding.

The irony is documented: Philip Morris International itself was found to have supplied cigarettes to criminal smuggling networks in Europe and the United States in the late 1990s and early 2000s. The company paid over $1.25 billion to the EU under a 2004 anti-smuggling agreement — yet continued to invoke the threat of smuggling as an argument against taxation and plain packaging in subsequent years.

The FCTC Protocol to Eliminate Illicit Trade in Tobacco Products, adopted in 2012, represents a multilateral effort to address the problem. The tobacco industry lobbied heavily against it during negotiations.

The industry's influence playbook has adapted to the digital environment. Social media influencers — often without disclosing payment or relationships — are used to promote newer nicotine products, particularly e-cigarettes, heated tobacco and nicotine pouches, to younger audiences. This extends the traditional marketing strategy (associating products with desirable lifestyles and identities) into platforms where traditional advertising rules are harder to enforce and disclosure requirements are inconsistently applied.

Online publication networks present a related challenge. Websites and newsletters that appear to cover vaping or tobacco harm reduction independently, but receive industry funding or are editorially influenced by industry-aligned foundations, produce content difficult to distinguish from independent journalism. The problem is not criticism of regulators per se — it is the absence of funding disclosure that allows undisclosed commercial interests to pass as independent commentary.

Coordinated social media campaigns around COP meetings and national regulatory consultations have also been documented, often amplifying talking points that align precisely with industry positions — sometimes using automated accounts or coordinated posting networks. As tobacco control debates increasingly play out on digital platforms, the industry's ability to shape public and political opinion through non-traditional channels continues to grow.